Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company announced topline study results from its Phase 2 investigational trial with CNM-ZnAg, an ionic solution of zinc and silver, for the treatment of non-hospitalized acutely symptomatic participants infected with COVID-19.
December 27, 2022
· 5 min read